Company intelligence / Profile preview

Kythera Biopharmaceuticals

Westlake Village, California, United States

Ownership: Private
Development stage: Other

Overview

Kythera Biopharmaceuticals' lead asset was KYBELLA (deoxycholic acid), the first FDA-approved non-surgical injectable for improvement of moderate to severe submental fullness (double chin). Clinical studies supported efficacy and safety in reducing submental fat. Another lead asset, setipiprant, was in early clinical development for androgenetic alopecia (male pattern hair loss) at the time of acquisition[1][3][4][7].

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Kythera Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kythera Biopharmaceuticals.

Explore the full profile